drugset / Trial / NCT01541202
Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
Timeline
- Start
- 2012-02
- Primary completion
- 2017-08
- Completion
- 2017-08
Outcome
Outcome not reported
Stopped: “Sponsor has designed another study to replace the current study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HUMAN NEUREGULIN-1 RECOMBINANT (177-237) | Protein / enzyme biologic | 0.8 ug/kg | Intravenous |